Head and Neck Atopic Dermatitis: Therapeutic Response After Switching to Upadacitinib in Moderate-to-Severe Atopic Dermatitis Patients Who Had Inadequate Response to Dupilumab. J of Skin 2026, 10 (2), s740. https://doi.org/10.25251/ztj3rn69.